The $1 Billion Disappearing Act That Could Starve Biotech's Pipeline

The administration framed the whole package as cutting "wasteful" spending, arguing the money was no longer needed because border crossings had fallen. Congress, predictably, disagreed.

Why Biotech Should Be Nervous

You might look at those line items and think: refugee services, housing counseling, migrant education. What does any of this have to do with drug development?

The answer is precedent.

This rescission didn't directly slash NIH's budget. But it lands in the middle of a sustained assault on federal research funding that has the biotech world on edge. The administration's FY2026 budget request proposed a 41% cut to NIH, roughly $19.6 billion stripped from the agency's approximately $48 billion budget. Congress rejected that proposal and kept NIH funding near prior levels, but the fight isn't over.

A competing Republican spending bill for HHS proposed a $7 billion cut (about 6% below 2025 levels), along with a 19% cut to the CDC and the complete elimination of AHRQ, the Agency for Healthcare Research and Quality. Meanwhile, thousands of NIH grants have already been terminated or frozen in the current cycle, with renewals running behind historical pace.

The rescission power is a tool. And once a tool works, it gets used again.

The Pipeline That Starts in a University Lab

For people outside biotech, it's easy to underestimate how much of the drug industry's innovation starts with federal money. NIH grants fund the basic science: understanding disease mechanisms, identifying targets, running early proof-of-concept experiments. University researchers do the risky, unglamorous work that no venture capitalist would touch.

That academic research becomes the foundation for biotech startups. A professor discovers a new pathway; a company spins out to develop it; eventually a drug reaches patients. Cut the grants, and you're not just hurting professors. You're thinning the startup funnel, delaying clinical trials, and reducing the number of new therapies that reach the market five or ten years from now.

J. Craig Venter, one of the scientists who helped sequence the human genome, put it bluntly: cutting NIH budgets is like a biotech company slashing its own pipeline. He called it "a disaster for the U.S. economy." And leading cancer research organizations have warned that the president's budget could devastate the U.S. research enterprise.

These aren't fringe voices. They're the people who build the science that becomes your medicine.

A Constitutional Showdown Is Brewing

The legal and political backlash has been bipartisan, which is notable in an era when almost nothing is. Senate Appropriations Chair Susan Collins called the rescission a clear violation of the law and a usurpation of Congress's appropriations powers. She pointed out that OMB withheld the money for months, then sent the package with no warning. Senator Patty Murray called it "theft from the American people, plain and simple." Even Republican Senator Lisa Murkowski voiced criticism.

The constitutional question at the heart of this fight is straightforward: does the president get to decide which programs Congress funds? Article I of the Constitution says no. The Impoundment Control Act was written specifically to prevent this kind of executive overreach, after Nixon tried the same thing in the 1970s.

But the Supreme Court hasn't ruled definitively on pocket rescissions. A prior emergency intervention sidestepped the core legality question, which means this tactic could face a fresh legal challenge. If it does, the outcome will shape how much power future presidents have to redirect (or simply destroy) congressionally approved spending.

The Bottom Line for Biotech

This $1 billion clawback didn't directly touch NIH grants. But it doesn't have to. The signal it sends is clear: appropriated funds aren't safe, and the executive branch is willing to use obscure procedural tools to override Congress's spending decisions.

For an industry that depends on stable, long-term federal research investment, that uncertainty is poison. Fewer grants mean fewer discoveries. Fewer discoveries mean fewer startups. Fewer startups mean fewer drugs. The biotech pipeline doesn't start in a boardroom; it starts in a lab funded by taxpayer dollars. And right now, the faucet is getting harder to turn on.

Novo Nordisk Really Wants You to Swallow a $1.4B Pill

Novo Nordisk just dropped $1.4 billion on a macrocycle startup days after another billion-dollar delivery deal. The injection giant is betting its future on pills, and the reason has everything to do with Eli Lilly.